Maplight Therapeutics Inc

CUSIP 56565P103COMMPLTQ1 2026

13D / 13G Filings

Schedule 13D/13G on record

Beneficial Filers

Distinct reporting persons

Largest Stake

45.1%

Max % of class reported

Institutional Holders

13F filers (latest quarter)

4 filings · latest Feb 17, 2026

#	Filed	Reporting Person	Form	% of Class	Shares	Filing
1	Feb 17, 2026	T. Rowe Price Investment Management, Inc.	13G	6.2%	2.80M	SEC
2	Feb 17, 2026	Forbion Growth Opportunities Fund III Cooperatief U.A.	13G	7.1%	3.23M	SEC
3	Nov 20, 2025	Catalyst4, Inc.	13D	45.1%	—	SEC
4	Nov 4, 2025	Novo Holdings A/S	13D	8.4%	—	SEC

Largest reported positions · latest quarter

#	Fund	Shares	Value
1	Novo Holdings A/S	3.69M	$74.95M
2	Fcpm III Services B.V.	3.23M	$65.59M
3	Goldman Sachs Group Inc	1.99M	$40.56M
4	Blackrock, Inc.	1.34M	$27.24M
5	Blue Owl Capital Holdings LP	1.01M	$20.45M
6	Nan Fung Group Holdings Ltd	971.3K	$19.75M
7	5am Venture Management, LLC	950.0K	$19.31M
8	Sanofi	912.0K	$18.54M
9	Pivotal Bioventure Partners Investment Advisor LLC	611.4K	$12.43M
10	Velan Capital Investment Management LP	492.9K	$10.02M